Peripheral Vascular Disease

Questions discussed in this category

What are your top takeaways from ACC 2024?

3 Answers available

Is ABI (Ankle Brachial index) lower limb arterial doppler not recommended if patient already has arterial stents in the legs, and if so, what other imaging modality would you consider as first-line?

1 Answer available

Based on results from the VOYAGER PAD trial, when would you consider the primary use of rivaroxaban with aspirin +/- clopidogrel as opposed to conventional aspirin +/- clopidogrel in patients undergoing lower extremity revascularization?

1 Answer available

What are your top takeaways from AHA 2023?

4 Answers available

Should a toe-brachial index be obtained in lieu of resting ABI as an initial screen for PAD in high-risk patients such as those with longstanding diabetes or advanced age with stiffened vessels?

1 Answer available

Is it sufficient to maintain patients with atrial fibrillation and established PAD on a DOAC or VKA alone, or is there an additional benefit to adding an antiplatelet agent for CVD benefit?

If so, would you prefer a P2Y12i over low-dose aspirin?

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2020 Mar 28

Rivaroxaban in Peripheral Artery Disease after Revascularization.

Circulation, 2023 Nov 13

Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A 20-Year Study.

Circulation, 2023 Nov 11

Arrhythmic Risk In Biventricular Pacing Compared with Left Bundle Branch Area Pacing: Results From The International LBBAP Collaborative Study (I-CLAS).

Circulation. Cardiovascular quality and outcomes, 2023 Nov 06

Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients with Atrial Fibrillation in the United States.

American heart journal, 2017 Apr 24

Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial.

The New England journal of medicine, 2023 Nov 11

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

American heart journal, 2023 Mar 25

Screening for peripartum cardiomyopathies using artificial intelligence in Nigeria (SPEC-AI Nigeria): Clinical trial rationale and design.

JAMA, 2023 Nov 11

Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial.

American heart journal, 2020 Oct 13

Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.

The New England journal of medicine, 2024 Apr 07

Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.

Circulation, 2016-12-13

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).

American heart journal, 2022 May 17

Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.

The New England journal of medicine, 2024 Apr 06

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

Related Topics